GH and IGF1 in cancer therapy resistance

Despite landmark advances in cancer treatments over the last 20 years, cancer remains the second highest cause of death worldwide, much ascribed to intrinsic and acquired resistance to the available therapeutic options. In this review, we address this impending issue, by focusing the spotlight on the rapidly emerging role of growth hormone action mediated by two intimately related tumoral growth factors - growth hormone (GH) and insulin-like growth factor 1 (IGF1). Here, we not only catalog the scientific evidences relating specifically to cancer therapy resistance inflicted by GH and IGF1 but also discuss the pitfalls, merits, outstanding questions and the future need of exploiting GH-IGF1 inhibition to tackle cancer treatment successfully.

Automated summary

This review article extensively discusses the role of growth hormone (GH) and insulin-like growth factor 1 (IGF1) in cancer treatment resistance, covering scientific evidence and the future need to exploit GH-IGF1 inhibition for successful cancer treatment.